Exact Sciences Corporation (BMV:EXAS)
Mexico flag Mexico · Delayed Price · Currency is MXN
890.12
-159.88 (-15.23%)
At close: Jul 29, 2025

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
2.87B2.57B2.35B
United States Revenue Growth
11.61%9.52%19.32%
Outside of United States Revenue
214.03M189.09M153.28M
Outside of United States Revenue Growth
13.19%23.37%30.19%
Revenue (Total)
3.08B2.76B2.50B
Revenue (Total) Growth
11.71%10.37%19.93%

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Screening Medicare Parts B & C Revenue
881.53M776.16M701.40M
Screening Medicare Parts B & C Revenue Growth
13.58%10.66%28.59%
Screening Commercial Revenue
1.27B1.12B992.24M
Screening Commercial Revenue Growth
13.51%12.71%33.50%
Screening Other Service Revenue
236.37M209.38M171.06M
Screening Other Service Revenue Growth
12.89%22.40%25.77%
Total Screening Revenue
2.39B2.10B1.86B
Total Screening Revenue Growth
13.47%12.83%30.88%
Precision Oncology Medicare Parts B & C Revenue
190.08M187.95M188.69M
Precision Oncology Medicare Parts B & C Revenue Growth
1.14%-0.39%-4.38%
Precision Oncology Commercial Revenue
193.70M190.60M181.32M
Precision Oncology Commercial Revenue Growth
1.63%5.12%2.14%
Precision Oncology International Revenue
214.03M189.09M153.28M
Precision Oncology International Revenue Growth
13.19%23.37%30.19%
Precision Oncology Other Service Revenue
96.93M87.36M105.83M
Precision Oncology Other Service Revenue Growth
10.94%-17.45%-2.83%
Total Precision Oncology Revenue
694.74M655.00M629.11M
Total Precision Oncology Revenue Growth
6.07%4.12%4.59%
COVID-19 Testing Revenue
--5.96M
COVID-19 Testing Revenue Growth
---89.75%
Revenue (Total)
3.08B2.76B2.50B
Revenue (Total) Growth
11.71%10.37%19.93%

EBT by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Income Before Tax
-1.04B-204.13M
Outside of United States Income Before Tax
145.00K2.38M
Outside of United States Income Before Tax Growth
-93.91%-
Updated Sep 30, 2025. Data Source: Fiscal.ai.